PGAM5-Mediated PHB2 Dephosphorylation Contributes to Diabetic Cardiomyopathy by Disrupting Mitochondrial Quality

Rongjun Zou1,2, Jun Tao3, Jie He1,2

  • 1Department of Cardiovascular Surgery, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong, China.

Research (Washington, D.C.)
|September 17, 2024
PubMed

Insights

Diabetic cardiomyopathy involves mitochondrial dysfunction. This study reveals the PGAM5-PHB2 pathway is key, with PGAM5 dephosphorylating PHB2 to regulate mitochondrial health in diabetes.

Area of Science:

  • Cardiovascular Biology
  • Mitochondrial Biology
  • Metabolic Disorders

Background:

  • Mitochondrial quality surveillance (MQS) disruption contributes to diabetic cardiomyopathy (DCM).
  • Cardiac phosphoglycerate mutase 5 (PGAM5) is upregulated in DCM.
  • PGAM5 is a mitochondrial Ser/Thr protein phosphatase.

Purpose of the Study:

  • To investigate the role of PGAM5 in DCM.
  • To identify molecular targets of PGAM5 in the heart.
  • To explore the PGAM5-PHB2 axis in diabetic cardiac dysfunction.

Main Methods:

  • Streptozotocin-induced DCM mouse model.
  • Cardiomyocyte-specific Pgam5 knockout mice.
  • Biochemical assays (co-immunoprecipitation, immunoblotting).
  • Mutagenesis studies and knockin mouse models.

Main Results:

  • Pgam5 knockout negated DCM-related cardiac deficits.
  • Hyperglycemia impaired mitochondrial function in control, but not Pgam5 knockout, cardiomyocytes.
  • PGAM5 dephosphorylates prohibitin 2 (PHB2) at Ser91.
  • PHB2 Ser91 phosphorylation is critical for hyperglycemic stress-induced mitochondrial dysfunction.
  • PHB2S91D knockin mice resisted diabetes-induced cardiac dysfunction.

Conclusions:

  • The PGAM5-PHB2 axis is a novel regulator of mitochondrial dysfunction in DCM.
  • Targeting the PGAM5-PHB2 interaction may offer therapeutic strategies for diabetic cardiomyopathy.